Phase 2/3 trial of VY-AADC01

Trial Profile

Phase 2/3 trial of VY-AADC01

Planning
Phase of Trial: Phase II/III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs AAV-hAADC (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Voyager Therapeutics
  • Most Recent Events

    • 30 Oct 2017 According to a voyager Therapeutics media release, the company plans to dose the first patient during the second quarter of 2018.
    • 12 Sep 2017 New trial record
    • 06 Sep 2017 According to a voyager Therapeutics media release, the company is planning to begin pivotal Phase 2/3 programm during late 2017 and to dose the first patient during the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top